Special Report: Recce Pharmaceuticals has secured patent acceptance in China for its synthetic anti-infectives RECCE® 327 (R327) and RECCE® 529 (R529) as it targets the growing global health ...

Recce entitlement offer shortfall placed to existing institutional and sophisticated investors, raising $7.4 million Shortfall placement concludes Recce’s $15.8 million capital raising to ...

Recce Pharmaceuticals secures patent acceptance in China for synthetic anti-infectives as it targets growing global health problem of antibiotic-resistant superbugs. Acceptance strengthens the ...

Recce receives firm commitments to place the full shortfall from its entitlement offer raising a total of $15.8 million to support phase III clinical trials. Don't miss out on the headlines from ...

But that doesn't mean long term investors can avoid big losses. For example, after five long years the Recce Pharmaceuticals Ltd (ASX:RCE) share price is a whole 62% lower. That is extremely sub ...